retatrutide clinical trials efficacy and safety of retatrutide, a GIP, GLP-1, and glucagon receptor agonist, in people with type 2 diabetes and inadequate glycaemic control with diet and exercise (TRANSCEND-T2D-1): a double-blind, randomised, phase 3 Lilly's triple agonist, retatrutide, delivered

Class-wide contraindications include personal or family history of medullary thyroid carcinoma (MTC) or multiple endocrine neoplasia type 2 (MEN2) GLP-1 receptors are expressed on C-cells

A broad spectrum of carotenoids (lutein, zeaxanthin, lycopene, astaxanthin) accumulate in skin tissue, functioning as singlet oxygen quenchers and lipid-phase antioxidants that attenuate ROS propagation

Patients should also be aware of rare but serious risks including pancreatitis, gallbladder disease, and potential worsening of diabetic retinopathy, particularly with rapid improvement in glucose control

The stability of S-acetylglutathione as it passes through the intestinal wall and into the bloodstream is well-documented in scientific literature